These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 36435510)

  • 1. Prognostic value and immunological role of FOXM1 in human solid tumors.
    Wei G; Yang X; Lu H; Zhang L; Wei Y; Li H; Zhu M; Zhou X
    Aging (Albany NY); 2022 Nov; 14(22):9128-9148. PubMed ID: 36435510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic and Immunological Roles of Cell Cycle Regulator CDCA5 in Human Solid Tumors.
    He J; Zhou X; Wang X; Zhang Q; Zhang L; Wang T; Zhu W; Liu P; Zhu M
    Int J Gen Med; 2022; 15():8257-8274. PubMed ID: 36438022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive bioinformatics analysis reveals the oncogenic role of FoxM1 and its impact on prognosis, immune microenvironment, and drug sensitivity in osteosarcoma.
    Shi S; Wang Q; Du X
    J Appl Genet; 2023 Dec; 64(4):779-796. PubMed ID: 37782449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pan-cancer analysis identifies RNF43 as a prognostic, therapeutic and immunological biomarker.
    Xu Y; Lin Z; Ji Y; Zhang C; Tang X; Li C; Liu T
    Eur J Med Res; 2023 Oct; 28(1):438. PubMed ID: 37848933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
    Wang N; Zhu L; Wang L; Shen Z; Huang X
    Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical implication and immunological landscape analyses of ANLN in pan-cancer: A new target for cancer research.
    Zhang L; Wei Y; He Y; Wang X; Huang Z; Sun L; Chen J; Zhu Q; Zhou X
    Cancer Med; 2023 Feb; 12(4):4907-4920. PubMed ID: 36030492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pan-cancer analysis of the oncogenic role of ribonucleotide reductase subunit M2 in human tumors.
    Li Y; Fu W; Geng Z; Song Y; Yang X; He T; Wu J; Wang B
    PeerJ; 2022; 10():e14432. PubMed ID: 36518297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pan-Cancer Integrated Analysis Identification of SASH3, a Potential Biomarker That Inhibits Lung Adenocarcinoma Progression.
    Chen X; Yuan Y; Ren W; Zhou F; Huang X; Pu J; Niu X; Jiang X
    Front Oncol; 2022; 12():927988. PubMed ID: 35756681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Invasive FoxM1 phosphorylated by PLK1 induces the polarization of tumor-associated macrophages to promote immune escape and metastasis, amplified by IFITM1.
    Xu R; Lee YJ; Kim CH; Min GH; Kim YB; Park JW; Kim DH; Kim JH; Yim H
    J Exp Clin Cancer Res; 2023 Nov; 42(1):302. PubMed ID: 37968723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SAAL1, a novel oncogene, is associated with prognosis and immunotherapy in multiple types of cancer.
    Yang W; Han B; Chen Y; Geng F
    Aging (Albany NY); 2022 Aug; 14(15):6316-6337. PubMed ID: 35963646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of FOXM1 in solid tumors: a systematic review and meta-analysis.
    Li L; Wu D; Yu Q; Li L; Wu P
    Oncotarget; 2017 May; 8(19):32298-32308. PubMed ID: 28427178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. H2A Histone Family Member Z (H2AFZ) Serves as a Prognostic Biomarker in Lung Adenocarcinoma: Bioinformatic Analysis and Experimental Validation.
    Li Z; Hu M; Qiu J; Feng J; Zhang R; Wu H; Hu G; Ren J
    Med Sci Monit; 2022 Jan; 28():e933447. PubMed ID: 35027526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of fatty acid metabolism-related molecular subtype biomarkers and their correlation with immune checkpoints in cutaneous melanoma.
    Xu Y; Chen Y; Jiang W; Yin X; Chen D; Chi Y; Wang Y; Zhang J; Zhang Q; Han Y
    Front Immunol; 2022; 13():967277. PubMed ID: 36466837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multidimensional pan-cancer analysis of DCAF13 and its protumorigenic effect in lung adenocarcinoma.
    Wei S; Lu K; Xing J; Yu W
    FASEB J; 2023 Apr; 37(4):e22849. PubMed ID: 36884358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker.
    Cheng X; Wang X; Nie K; Cheng L; Zhang Z; Hu Y; Peng W
    Front Immunol; 2021; 12():646523. PubMed ID: 33679809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD1B is a Potential Prognostic Biomarker Associated with Tumor Mutation Burden and Promotes Antitumor Immunity in Lung Adenocarcinoma.
    Li Z; Feng Y; Li P; Wang S; Liu X; Xia S
    Int J Gen Med; 2022; 15():3809-3826. PubMed ID: 35418778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma.
    Huang S; Sun L; Hou P; Liu K; Wu J
    Front Immunol; 2022; 13():944898. PubMed ID: 36148220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An integrated model of CDCA5 and FOXM1 expression combined with a residual disease that predicts prognosis in ovarian cancer patients.
    Zhang Q; Zhang R; Liu M; Wu H; Yang B
    Cell Mol Biol (Noisy-le-grand); 2023 Oct; 69(10):143-149. PubMed ID: 37953569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of FSCN1 and FOXM1 are associated with poor prognosis of adrenocortical carcinoma patients.
    Liang J; Liu Z; Wei X; Zhou L; Tang Y; Zhou C; Wu K; Zhang F; Zhang F; Lu Y; Zhu Y
    BMC Cancer; 2019 Nov; 19(1):1165. PubMed ID: 31783819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PRKCSH serves as a potential immunological and prognostic biomarker in pan-cancer.
    Wang Q; Wang X; Li J; Yin T; Wang Y; Cheng L
    Sci Rep; 2024 Jan; 14(1):1778. PubMed ID: 38245572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.